Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 331Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × uridine triacetate × Gastrointestinal × Clear all
NCT00024427 2012-06-28

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Wellstat Therapeutics

Phase 3 Completed
250 enrolled
Gastrointestinal

Pancreatic Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT00004233 2011-07-25

S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach

SWOG Cancer Research Network

Phase 2 Completed
65 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡